HTG Molecular Diagnostics and Firalis Announce an Agreement Enabling Firalis’ Commercialization of Theranostic and Research Products and Services Based on HTG EdgeSeq Technology

HTG Molecular Diagnostics (NASDAQ:HTGM) a provider of instruments, reagents and services for molecular profiling applications, and Firalis S.A., a provider of bioanalytical services and biomarker-based products and services, today announced a non‑exclusive license and supply agreement that will enable Firalis to commercialize a next‑generation sequencing (NGS)‑based theranostic product and services to predict rheumatoid arthritis patients response to anti‑TNFα therapy, and other research products and services for mRNA profiling of inflammatory‑autoimmune disorders.

As quoted in the press release:

The Agreement is a next step in the parties’ relationship following the successful adaptation of Firalis’ BIOPRED* research‑use assay to HTG EdgeSeq technology. Under the Agreement, HTG will supply assay components to Firalis, who will manufacture, obtain applicable regulatory approvals for and sell the BIOPRED assay as kits and Firalis-based services in the applicable diagnostic and research fields worldwide. All such kits and services will be automated on HTG EdgeSeq systems purchased directly from HTG by end users.

“Firalis was one of the first adopters of the HTG EdgeSeq system in Europe, and we are pleased to support them in the next steps in this personalized medicine initiative,” said TJ Johnson, Chief Executive Officer of HTG. “Strategic supply and non‑exclusive technology out‑licensing is another way to further our business objectives of market recognition and expansion and revenue growth.

Click here to read the full press release.